Abstract
Cancer biology as seen from chromosome 11 involves a plethora of mechanisms for chromosomal changes. The high frequency of repeated elements, the presence of active retrotransposons, the appearance of fragile sites, and the presence (and amplification) of drug resistance genes are all expected to destabilize the integrity of this chromosome. Thus, it is not unexpected that chromosome 11 is often mutated in a variety of tumors. Here, we review genes relevant to lung carcinogenesis and progression. Numerous loci and genes will be omitted since their role appears to be restricted to organ sites other than lung (i.e., the KAI gene at 11p11.2 which is involved in metastatic prostate cancer; the EXT2 gene at 11p11.2, which is one of the genes responsible for hereditary multiple exostoses; the WT1 gene at 11p13, which is frequently mutated in nephroblastoma; the TSG101 gene at 11p15.1-2, which may play a role in breast cancer; the ST5 (HTS1) gene at 11p15.3-4, which may be responsible for suppression of HeL a cell somatic cell hybrids). These genes may represent tissue-specific alterations that push certain types of cells into uncontrolled growth. In contrast, chromosome 11 also has genes for basic metabolic processes that are integral to the proliferation of cells (i.e., RRM1) and these are expected to be involved in a broad range of tumors. This review specifically focuses on HRAS, RRM1, MEN1, PPP2R1B, and ATM. Studies of the chromosomal abnormalities that underly cancer has produced a greater understanding of the normal patterns of gene regulation in healthy cells. Imprinting is one example of this, and the future promises to reveal much more.
Keywords: Lung Cancer, Chromosome 11, EXT2 gene, Nephroblastoma, Carcinogenesis, PPP2R1B, DUTT1, NCAM-related protein, LOH
Current Genomics
Title: The Pathogenesis of Lung Cancer and Chromosome 11
Volume: 1 Issue: 3
Author(s): Diana M. Pitterle, Young-Chul Kim, Youjia Cao, Ashish Gautam, Baohui Zhao, Amy Beck and Gerold Bepler
Affiliation:
Keywords: Lung Cancer, Chromosome 11, EXT2 gene, Nephroblastoma, Carcinogenesis, PPP2R1B, DUTT1, NCAM-related protein, LOH
Abstract: Cancer biology as seen from chromosome 11 involves a plethora of mechanisms for chromosomal changes. The high frequency of repeated elements, the presence of active retrotransposons, the appearance of fragile sites, and the presence (and amplification) of drug resistance genes are all expected to destabilize the integrity of this chromosome. Thus, it is not unexpected that chromosome 11 is often mutated in a variety of tumors. Here, we review genes relevant to lung carcinogenesis and progression. Numerous loci and genes will be omitted since their role appears to be restricted to organ sites other than lung (i.e., the KAI gene at 11p11.2 which is involved in metastatic prostate cancer; the EXT2 gene at 11p11.2, which is one of the genes responsible for hereditary multiple exostoses; the WT1 gene at 11p13, which is frequently mutated in nephroblastoma; the TSG101 gene at 11p15.1-2, which may play a role in breast cancer; the ST5 (HTS1) gene at 11p15.3-4, which may be responsible for suppression of HeL a cell somatic cell hybrids). These genes may represent tissue-specific alterations that push certain types of cells into uncontrolled growth. In contrast, chromosome 11 also has genes for basic metabolic processes that are integral to the proliferation of cells (i.e., RRM1) and these are expected to be involved in a broad range of tumors. This review specifically focuses on HRAS, RRM1, MEN1, PPP2R1B, and ATM. Studies of the chromosomal abnormalities that underly cancer has produced a greater understanding of the normal patterns of gene regulation in healthy cells. Imprinting is one example of this, and the future promises to reveal much more.
Export Options
About this article
Cite this article as:
Pitterle M. Diana, Kim Young-Chul, Cao Youjia, Gautam Ashish, Zhao Baohui, Beck Amy and Bepler Gerold, The Pathogenesis of Lung Cancer and Chromosome 11, Current Genomics 2000; 1 (3) . https://dx.doi.org/10.2174/1389202003351373
DOI https://dx.doi.org/10.2174/1389202003351373 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents The Target of Regulating The ATP-binding Cassette A1 Protein (ABCA1): Promoting ABCA1-Mediated Cholesterol Efflux in Different Cells
Current Pharmaceutical Biotechnology Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Role of Carboxypeptidase N Invasion and Migration in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Androgen Receptor Antagonists in the Treatment of Prostate Cancer
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Different Gene Therapy Strategies: A Overview for Prostate Cancer
Current Gene Therapy Pleiotropic Effects of Tocotrienols and Quercetin on Cellular Senescence: Introducing the Perspective of Senolytic Effects of Phytochemicals
Current Drug Targets Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications
Current Medicinal Chemistry Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Current Cancer Drug Targets Highlights on Medical Treatment of Uterine Fibroids
Current Pharmaceutical Design P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry Synthesis of Novel 1,4-Substituted 1,2,3-Triazoles by Water-Soluble (Salicyladimine) <sub>2</sub>Cu Complex Catalyzed Azide-Alkyne Cycloaddition in Water
Letters in Organic Chemistry Fertility Preservation for Young Women with Cancer: Hope for the Future
Current Women`s Health Reviews Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Improving of Nutraceutical Features of Many Important Mediterranean Vegetables by Inoculation with a New Commercial Product
Current Pharmaceutical Biotechnology Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery